Med. praxi. 2013;10(2):57-63

Sildenafil in treating erectile dysfunction

MUDr.Ondřej Trojan
TH Klinika, s. r. o., Praha

The article initially describes the history of the discovery of the first PDE5 inhibitor designed to treat erectile dysfunction. It explains the mechanism

of erection and the conditions for its proper functioning. It elucidates the mechanism of action of PDE5 inhibitors in treating erectile

dysfunction, summarizes the experience with sildenafil during its 15 years of existence, its indications as well as contraindications, and highlights

some mistakes physicians make in the management. Erectile dysfunction often serves as an initial sign of a somatic, particularly cardiovascular,

disease; therefore, it is important that this sensitive issue be communicated about with patients and searched for by general practitioners.

The article also outlines the model of an optimal combined approach using psychotherapy with pharmacotherapy. Such therapeutic strategy

further potentiates the effect of sildenafil alone. Some previously published facts are presented and updated with new knowledge

for everyday diagnostic-therapeutic use.

counter-indications, psychotherapy, diabetes mellitus, hypertension, psychological disorders.

Keywords: erectile dysfunction, PDE5 inhibitors, sildenafil citrate, discovery, mechanism of action, experience, treatment errors, indication,

Published: February 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Trojan O. Sildenafil in treating erectile dysfunction. Med. praxi. 2013;10(2):57-63.
Download citation

References

  1. Trojan O. Možnosti léčby erektilní dysfunkce: kde jsme a kam se ubíráme? Causa Subita 2003.
  2. ESSM Syllabus of Sexual Medicine 2012.
  3. Katzenstein O. VIAGRA "The Remarkable Story of the Discovery and Launch", Commemorative Edition, Pfizer, 2007.
  4. Wikipedie: http://en.wikipedia.org/wiki/Sildenafil.
  5. Goldstein I, et al. Oral sildenafil in the treatment of erectile dysfunction, N Engl J Med 1998; 338(20) ( pp.1397-1404). Go to original source... Go to PubMed...
  6. Beckman JT, et al. Diagnostika a farmakoterapie erektilní dysfunkce. Medicína po promoci 2006; 30-40.
  7. Riley A, Riley E. Int J Clin Pract 2000; 54(4): 220-224. Go to original source... Go to PubMed...
  8. Goldstein I, et al. International Educational Initiative on Erectile Function, 2002.
  9. Auld RB, Brock G. Sexuality and erectile dysfunction: results of a national survey, J Sex Repr Med 2002; 2: 50-54. Go to original source...
  10. Lue TF. Erectile dysfunction, New England Journal of Medicine 2000; 342(24): ( pp.1802-1813). Go to original source... Go to PubMed...
  11. Utiger RD. A pill for impotence. N Engl J Med 1998; 338: 1458-1459. Go to original source... Go to PubMed...
  12. Aytaç IA, et al. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. Br J Urol Int 1999; 84: 450-456. Go to original source...
  13. Rosen RC, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830. Go to original source... Go to PubMed...
  14. Študent V, et al. Systém hodnocení erektilní dysfunkce pomocí stupnice EHS, Urol List 2008; 6(4): 38-39.
  15. Goldstein I, et al. The erection hardness score and its relationship to successful sexual intercourse. J.Sex Med 2008; 5: 2374-2380. Go to original source... Go to PubMed...
  16. Jackson G, et al. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine, J Sex Med. 2006; 3(1): 28-36. Go to original source... Go to PubMed...
  17. Nehra A, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87(8): 766-778. Go to original source... Go to PubMed...
  18. Gingell, et al. Duration of action of sildenafil citrate in men with erectile dysfunction. J Sex Med 2004; 1: 179-184. Go to original source... Go to PubMed...
  19. Fink HA, Mac Donald R, et al. Sildenafil for male erectile dysfunction. A systematic review and metaanalysis. Arch Intern Med 2002; 162: 1349-1360. Go to original source... Go to PubMed...
  20. Stief C, Porst H, et al. Vardenafil Study Group. Sustained efficacy and tolerability with Vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 2004; 58: 230-239. Go to original source... Go to PubMed...
  21. McCullough AR. Four-year review of Sildenafil citrate. Rev Urol 2002; 4: S26-38. Go to PubMed...
  22. Padma-Nathan H, et al. Urology 2002; 60(Suppl 2B): 67-90; Brock G, et al. J Urol 2002; 167(Suppl 4): 178; Goldfischer E et al. J Urol 2002; 167(Suppl 4): 178. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.